New strategy for delivering cGAMP molecules
By using 200 nanometers in diameter and positively charged surface modified silica nanoparticles, cGAMP is delivered to the cells, activate the STING signaling pathway, solving the problem that cGAMP is difficult to pass through the cell membrane, achieving efficient pharmaceutical applications, and enhancing the immune response And new treatment options are provided.
Patent Information
- Application Number
- CN202411326846.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-23
- Publication Date
- 2024-12-06
AI Technical Summary
Because of its negative charge and strong hydrophilicity, the cyclic GMP-AMP (cGAMP) molecule is difficult to pass through the highly hydrophobic cell membrane, resulting in its low delivery efficiency in medical applications, limiting its clinical application.
Silica nanoparticles with a diameter of 200 nanometers, spiked with solid silica and positively charged surfaces are used to deliver cGAMP to the cells, activate the STING signaling pathway, and achieve pharmaceutical purposes.
Through this method, cGAMP can be effectively delivered into cells, activate the STING pathway, and enhance the immune response, providing new potential pharmaceutical applications for the treatment of tumors, infectious diseases and autoimmune diseases, avoiding the complex preparation of traditional liquid nanocarriers and Save the puzzle.
Smart Images

Figure CN119074933A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biomedicine technology and more specifically relates to a new strategy for efficiently delivering cyclic GMP-AMP for pharmaceutical purposes. Background Art
[0002] Stimulator of interferon genes (STING) is a key molecule in the innate immune response. It plays an important role in the treatment and prevention of tumors, infectious diseases, autoimmune diseases, etc., and is also an important emerging drug development target. Cyclic GMP-AMP (cGAMP) is an endogenous STING signaling pathway agonist. After binding to the STING protein in the cytoplasm, it activates the downstream signaling pathway, induces the production of type I interferon, and regulates acquired immunity through chemokines (Cxcl10), interleukins (IL-6, IL-1β) and tumor necrosis factor (TNFα). Because cGAMP is a natural endogenous agonist, it has a complete metabolic pathway, high biocompatibility, and good drugability, and has attracted widespread attention. Patent numbers (CN2022800 54499.7, CN202280036836.X, CN202311114635.X, CN202180071894.1, CN202010943008.7, etc.) disclose the potential application of STING natural agonists for tumor treatment. However, cGAMP molecules are negatively charged and highly hydrophilic, and cannot freely penetrate the hydrophobic cell membrane, which has become an important obstacle to the application of cGAMP in molecular medicine. Researchers have developed a variety of delivery systems in an attempt to deliver cGAMP into cells for pharmaceutical applications. For example, patent numbers CN202410262607.0 and CN202310172015.5 disclose methods for cGAMP delivery by assembling nanoparticles using polypeptides; patent number CN202110488614.9 discloses a method for co-delivering cGAMP and other drug molecules using lipid carriers; patent number CN202310378745.0 discloses a method for delivering cGAMP using exosomes; patent number CN202211412211.7 discloses a method for delivering cGAMP using micelles. The above-mentioned published patents and available literature mostly use liquid-based nanocarriers, which have the disadvantages of complex preparation processes and difficulty in storage and transportation at room temperature. So far, there have been no reports on the use of silica nanoparticles with solid spikes on the surface for cGAMP delivery.
[0003] Silica is a low-toxic, highly biocompatible material that is widely used in the food and pharmaceutical fields. For example, the U.S. Food and Drug Administration (USFDA) and the China Food and Drug Administration allow the addition of silica to infant formula; a silica particle with a diameter of 100 nanometers is a legal food additive; and at least 11 silica-containing nanoparticles have been used clinically (1). We previously reported and published a method for synthesizing silica nanoparticles with different spike lengths using the classic Stöber method, and selected a class of nanoparticles for the delivery of small nucleic acids (2), but it is unclear whether this type of carrier can deliver smaller molecular weight cyclic dinucleotides. Summary of the invention
[0004] The technical problem to be solved by the present invention is to overcome the difficulty of cGAMP in penetrating cell membranes to exert its efficacy, which has hindered its clinical application. The present invention provides a new strategy for delivering the natural activator of interferon-stimulated factor gene (STING), cyclic GMP-AMP (cGAMP) molecules, into cells using silica nanoparticles with a diameter of 200 nanometers, solid silica spikes on the outside, positively charged surface modification, and spike lengths ranging from 40 to 60 nanometers, to activate the STING pathway to increase immunity. The administration methods include but are not limited to nasal drops, intramuscular injections, and tail vein injections.
[0005] The above-mentioned object of the present invention specifically comprises the following steps to achieve:
[0006] (1) Add the synthesized specific silica nanoparticles SSN-2 into a solvent (pure water, PBS or saline, etc.), disperse them by ultrasonication, and prepare a 10 mg / mL suspension;
[0007] (2) Dissolve cGAMP in DMSO or pure water to prepare a 1 mg / mL solution;
[0008] (3) Mix a specific amount of SSN-2 and cGAMP and place at room temperature for 5 min;
[0009] (4) The mixed solution prepared in step (3) is dripped into the nose or injected into the target animal. BRIEF DESCRIPTION OF THE DRAWINGS
[0010] Figure 1 Schematic diagram of qRT-PCR results of intramuscular injection in Example 1 of the present invention
[0011] Figure 2 Schematic diagram of qRT-PCR results of tail vein injection in Example 2 of the present invention
[0012] Figure 3 Schematic diagram of qRT-PCR results of nasal administration in Example 3 of the present invention DETAILED DESCRIPTION
[0013] The present invention is further described below in conjunction with the accompanying drawings and specific examples, but the examples do not limit the present invention in any form. Unless otherwise specified, the reagents, methods and equipment used in the present invention are conventional reagents, methods and equipment in the art.
[0014] The principle of the invention is to deliver cGAMP into cells through silica nanoparticles with surface spikes, activate STING to clear the meridians, thereby inducing autoimmunity to achieve a therapeutic effect.
[0015] Unless otherwise specified, the reagents and materials used in the following examples are commercially available.
[0016] Example 1 An in vivo administration method (muscular injection) capable of efficiently delivering cGAMP
[0017] Mice were randomly divided into the following four groups: saline, SSN-2, cGAMP, SSN-2+cGAMP (administered for 12 h), with 3 mice in each group. SSN-2 (ultrasound dissolved in saline), cGAMP (dissolved in saline), and a mixture of SSN-2 and cGAMP incubated for 30 min were prepared, and the administration system was 200 μL. The dosage was 0.2 mg / kg SSN-2 and 1 mg / kg cGAMP. After preparation, the mice were caged according to the groups. After the mice were fixed, a 1 mL syringe was used to inject the drug into the inner muscle of the left thigh of the mice. After 12 h, the mice were euthanized, 200 μL of blood was collected in a 1.5 mL EP tube with anticoagulant, and red blood cell lysis solution (Solebo R1010) was added to lyse the red blood cells. 1 mL Trizol was added to extract RNA, and the mRNA levels of ifnβ and tnfα were detected by qRT-PCR.
[0018] Example 2 An in vivo administration method capable of efficiently delivering cGAMP (tail vein injection)
[0019] Mice were randomly divided into the following four groups: saline, SSN-2, cGAMP, SSN-2+cGAMP (administered for 12 h), with 3 mice in each group. SSN-2 (ultrasound dissolved in saline), cGAMP (dissolved in saline), and a mixture of SSN-2 and cGAMP incubated for 30 min were prepared, and the administration system was 200 μL. The dosage was 0.2 mg / kg SSN-2 and 1 mg / kg cGAMP. After preparation, the mice were caged according to the groups, and the mice were fixed and injected into the tail vein of the mice using a 1 mL syringe. After 12 h, the mice were euthanized, 200 μL of blood was collected in a 1.5 mL EP tube with anticoagulant, and red blood cell lysis solution (Solebo R1010) was added to lyse the red blood cells, and 1 mL Trizol was added to extract RNA, and the mRNA levels of ifnβ and tnfα were detected by qRT-PCR.
[0020] Example 3 An in vivo administration method capable of efficiently delivering cGAMP (nasal administration)
[0021] Mice were randomly divided into the following six groups: PBS, SSN-2, cGAMP, SSN-2+cGAMP (administration for 0.5 h), SSN-2+cGAMP (administration for 1 h), SSN-2+cGAMP (administration for 2 h), with 3 mice in each group. SSN-2 (ultrasound dissolved in PBS), cGAMP (dissolved in PBS), and the mixture of SSN-2 and cGAMP after incubation for 30 min were prepared respectively, and the administration system was 20 μL. The dosage was 0.2 mg / kg SSN-2 and 0.0125 mg / kg cGAMP. After preparation, the mice were caged according to the groups, and after the mice were fixed, the mice were nasally administered with a syringe. After 0.5 h and 1 h, the mice in the SSN-2+cGAMP (administration for 0.5 h) group and the SSN-2+cGAMP (administration for 1 h) group were euthanized, and the brain tissues (olfactory bulb, cerebrum and cerebellum) were dissected, washed with PBS, and then ground with 1 mL Trizol to extract RNA. The mice in the remaining groups were euthanized 2 h after administration, and the same brain tissue was dissected and ground with Trizol to extract RNA for qPCR detection of IFN mRNA levels.
Claims
1. A novel strategy for in vivo delivery of cGAMP for medical purposes based on silica nanoparticles SSN-2.
2. The silica nanoparticle SSN-2 according to claim 1 specifically refers to a solid nanoparticle with a diameter of 200 nanometers, a surface modified to be positively charged, and a solid spike on the outside, with a spike length of 40-60 nanometers and uniform size.
3. The pharmaceutical application method according to claim 1 includes but is not limited to nasal administration, intramuscular injection and intravenous injection.
4. The in vivo delivery of cGAMP according to claim 1, wherein the application method includes but is not limited to physically mixing SSN-2 in a pharmaceutically acceptable solvent such as physiological saline or sterile water to prepare a premixed solution; or mixing SSN-2 and cGAMP in a certain ratio to prepare a powder.
5. The cGAMP molecule according to claim 1, specifically refers to the STING activator cyclic GMP-AMP and its pharmaceutically effective derivatives, such as 2',3'-cGAMP molecules, 3'3'-cGAMP molecules, pharmaceutically effective salts of cGAMP molecules, cyclic GMP-GMP and cyclic AMP-AMP, etc.
6. The medical application according to claim 3, its purpose includes but is not limited to the prevention, treatment and adjuvant treatment of tumors, infectious diseases and autoimmune diseases.
Citation Information
Patent Citations
Application of pidotimod and natural immune agonist compound in preparation of antitumor drugs and like
CN114224905A
Preparation and composition of novel 4 (3H)-quinazolinone analogue / cyclic dinucleotide cGAMP co-carrier liposome and application of novel 4 (3H)-quinazolinone analogue / cyclic dinucleotide cGAMP co-carrier liposome in antitumor drugs
CN115252554A
Polymer, polymer micelle and preparation method and application thereof
CN115926177A
Self-assembled core-based nanofiber peptide PEG-Q11T as well as preparation method and application of self-assembled core-based nanofiber peptide PEG-Q11T
CN116063402A
Engineered exosome for pancreatic cancer immunotherapy and preparation method thereof
CN116370647A
